MedTrace Logo

Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension

NCT00004754 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available.

II. Obtain additional safety information on continuous infusion epoprostenol. III. Obtain additional information on economic resource health consumption.

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

epoprostenol

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Adaani E. Frost · Baylor College of Medicine

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004754 on ClinicalTrials.gov